<DOC>
	<DOCNO>NCT02022358</DOCNO>
	<brief_summary>Methotrexate one effective chemotherapy drug treatment osteosarcoma type bone sarcoma treat way osteosarcoma . However , frequently lead sore mouth , tummy pain increase risk develop infection . The investigator try save `` rescue '' normal cell side effect methotrexate give drug call folinic acid . Folinic acid start 24 hour methotrexate give regularly methotrexate level really low dangerous normal cell anymore . Despite rescue , side effect still problem many patient well enough receive subsequent chemotherapy time . Almost half planned chemotherapy cycle give time due methotrexate side effect . In study investigator examine add drug call glucarpidase folinic acid helpful . Glucarpidase enzyme inactivates methotrexate blood stream . Lower methotrexate concentration blood stream lead few side effect . The investigator would like see glucarpidase help patient chemotherapy time , reduce side effect methotrexate .</brief_summary>
	<brief_title>Will Glucarpidase After Methotrexate Treatment Bone Sarcoma Lead Fewer Side Effects Reduce Chemotherapy Delays ?</brief_title>
	<detailed_description>In study patient receive 4 course high-dose methotrexate . High-dose methotrexate normally give weekly interval , block two.The first two course give week 1 &amp; 2 ; second two course week 4 &amp; 5 . Two course give folinic acid rescue ( standard high-dose methotrexate ) , two give glucarpidase rescue well folinic acid . This enable u compare whether difference side effect without glucarpidase also quickly patient recover . Half patient receive standard high-dose methotrexate week 1 &amp; 2 high-dose methotrexate glucarpidase week 4 &amp; 5 ( arm A ) half patient first high-dose methotrexate glucarpidase week 1 &amp; 2 standard high-dose methotrexate week 4 &amp; 5 ( arm B ) . All patient receive methotrexate daily blood test monitor level methotrexate body , monitor kidney function . However , patient study extra blood test chemotherapy drug level glucarpidase antibody level . During hospital admission chemotherapy , blood sample take follow : Day 1 : Just start methotrexate ( extra blood test ) end methotrexate infusion ( extra blood test ) Day 2 : 24 hour start methotrexate ( routine blood test ) 20 minute 24-hour blood test ( i.e . glucarpidase/placebo infusion ) ( extra blood test ) Day 3+ : Routine daily blood test body get rid methotrexate Extra blood sample also take 15 day start cycle 1 month , 3 6 month , start second cycle . Patients also ask complete mucositis assessment quality life questionnaire .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Written inform consent patient parent/guardian Diagnosis high grade osteosarcoma , localise metastatic high grade osteosarcoma second malignancy spindle cell sarcoma bone relapse high grade osteosarcoma Ability comply study follow procedure ( WHO performance scale 02 ) No concomitant anticancer investigational drug study complete resolution toxicity relate previous treatment Life expectancy least 3 month Haematopoietic function : Absolute neutrophil count ≥1 x109/L , Platelets ≥75 x109/L Hepatic function : Bilirubin ≤1.5 x ULN Renal function : Glomerular Filtration Rate ( radioisotope ) ≥ 70 ml/min/1.73m2 Previous treatment glucarpidase Pregnant breast feed woman ( patient reproductive potential either gender must use contraception* ) Concomitant treatment agent interact methotrexate metabolism excretion Serous effusion , include ascites pleural effusion</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Osteosarcoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Glucarpidase</keyword>
	<keyword>Mucositis</keyword>
</DOC>